Eisai Co., Ltd.
Stock Price Chart
2026/01/16 UpdatedPrice Trend
2026/01/16 UpdatedPrice & Trading Details
2026/01/16 UpdatedPRICE
TRADING
Analyst Recommendations 13 analysts
Updated 2026/01/11Shareholder Composition
Updated 2026/01/11Top Mutual Funds / ETFs
Updated 2026/01/11Major Holders
Updated 2026/01/11| Fund Name | Ownership | Shares | Change |
|---|---|---|---|
|
VANGUARD SPECIALIZED FUNDS-Vanguard Health Care Fund
|
8.5M | -11.67% | |
|
VANGUARD STAR FUNDS-Vanguard Total International Stock Index Fund
|
3.8M | -0.04% | |
|
VANGUARD TAX-MANAGED FUNDS-Vanguard Developed Markets Index Fund
|
2.4M | +2.35% | |
|
iShares Trust-iShares Core MSCI EAFE ETF
|
1.8M | +1.17% | |
|
HARTFORD MUTUAL FUNDS INC/CT-The Hartford International Value Fund
|
1.0M | +10.40% | |
|
Fidelity Concord Street Trust-Fidelity International Index Fund
|
924.1K | -0.12% |
| Institution | Ownership | Shares | Change |
|---|---|---|---|
|
Pacer Advisors, Inc.
|
2.4K | -6.70% |
Dividend History
Updated 2026/01/11| Year | Dividend | Change |
|---|---|---|
| 2025 | ¥160 | 0.0% |
| 2024 | ¥160 | 0.0% |
| 2023 | ¥160 | 0.0% |
| 2022 | ¥160 | 0.0% |
| 2021 | ¥160 | - |
Financial Performance
2026/01/11 UpdatedRevenue & Profit
Margins
Cash Flow
Financial Health
| 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | ¥756,226M | ¥744,402M | ¥741,751M | ¥789,400M |
| Gross Profit | ¥581,395M | ¥566,566M | ¥586,417M | ¥620,593M |
| Operating Income | ¥53,750M | ¥40,040M | ¥53,407M | ¥54,377M |
| Pretax Income | ¥56,150M | ¥47,278M | ¥64,211M | ¥64,584M |
| Net Income | ¥47,954M | ¥55,432M | ¥42,407M | ¥46,433M |
| EPS | ¥167.25 | ¥193.31 | ¥147.86 | ¥163.76 |
| Operating Margin | 7.11% | 5.38% | 7.20% | 6.89% |
| Balance Sheet | ||||
| Total Assets | ¥1,239,315M | ¥1,263,350M | ¥1,393,799M | ¥1,386,547M |
| Total Equity | ¥748,821M | ¥799,959M | ¥875,614M | ¥841,417M |
| Total Liabilities | ¥490,494M | ¥463,391M | ¥518,185M | ¥545,130M |
| Cash | ¥309,633M | ¥267,350M | ¥304,678M | ¥265,561M |
| Interest-bearing Debt | ¥94,893M | ¥126,105M | ¥159,405M | ¥187,523M |
| Equity Ratio | 60.42% | 63.32% | 62.82% | 60.68% |
| D/E Ratio | 0.13 | 0.16 | 0.18 | 0.22 |
| Cash Flow | ||||
| Operating CF | ¥117,590M | -¥1,772M | ¥55,993M | ¥30,117M |
| Investing CF | -¥28,848M | -¥22,723M | -¥25,321M | -¥10,097M |
| Financing CF | -¥48,967M | -¥24,522M | -¥22,720M | -¥57,809M |
| Free CF | ¥77,123M | -¥36,331M | ¥31,170M | ¥7,148M |
| Efficiency | ||||
| ROE | 6.40% | 6.93% | 4.84% | 5.52% |
| ROA | 3.87% | 4.39% | 3.04% | 3.35% |
Latest IR Information
-
No IR information found for this company.
Searched stock code: 4523
Latest News (5 items)
-
Average Analyst Rating: buy
Average Target Price: ¥4,906
Rating Score: 2.42 (Based on 13 analysts)
※1=Strong Buy, 5=Strong Sell
Company Information
About
Eisai Co., Ltd. engages in the research and development, manufacture, sale, and import and export of pharmaceuticals. It also offers prescription medicines. In addition, the company focuses on neurology and oncology and therapeutic areas. The company was formerly known as Nihon Eisai Co., Ltd. and changed its name to Eisai Co., Ltd. in 1955. Eisai Co., Ltd. was incorporated in 1941 and is headquartered in Tokyo, Japan.